ZNF333

Across TCGA pan-cancer cohorts, ZNF333 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ZNF333 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher ZNF333 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZNF333 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

UCS, LGG, and LIHC are the cancer types where ZNF333 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	DFS	Median	All	0.068	0.524	<.001	48	view →
LGG	OS	Median	All	0.133	0.811	<.001	12	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
UCEC	DFS	Median	All	0.972	0.828	.019	8	view →
SCLC	OS	Median	All	0.178	0.660	.002	6	view →
STAD	OS	Median	IV	0.805	0.283	.031	6	view →
LUSC	DFS	Median	II,III,IV	0.185	0.709	.018	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ZNF333–UCS (DFS)

Open the UCS breakdown →